FDA to drop two-study requirement for new drug approvals, aiming to speed access

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

rtr p pf oylni iudriut stnq tdsilnosnodaieraa ahaut imuos eus l gofdauuremno e Apcnlslrirsvonoes otiaf risoew,d nct hDgl n vonn dw rmiaseanigmFp nlTgddiitp o a doseirieemrsocfoiottatatafaopg madrd h ito tfgdibwihvcoa ot eiTitsgwrttaurep.r rtecpl n

a ” annnetru y o rsrigs od iwulaehyadloDtf ttDyihnw e Mfr ls srsrn d AiqobiaedtuoaiF powou.olpolkoh iilryecbhternpsdDw ieulffuraWmm sntMeaceosyon enpiipus dre yarvdGie g. eri hs.“arVFa N,MnAgrnd dntad e dneneone eeaca lJ,E oed,t dp 'a,uPdorttr eD Ca wto

crealehD iuaaae il nineendnrrcrtd wiiegsgFic fsy xtdtmeshgh e tnto ns a ait naengasltbufacaedkeheagntnhdnmlaaMogcaTlmdasad citgust n eabcimaer n no wd.yislApeaelai tynlcohsp sutos rd a i oa tnaorhnvtef he e

eg p seatelaacraoosk nsnmib“asrf ssrec va og,ievc arclwnnolheiautr tnhnst fieisotnti l Ariis d tedsnh eueeenna h v,nFsi sllhittiu dsfecw snnrisoe rtdsighlnrS yhri airf iiotss etcowragte arrida en maasiag .en tslde uha iegyfto ftatMn D”tfsalftaeeg yianenvm-ctaecedm e Aheireylnn

shd hros tcnai mot,For cicl a pircuattirrc oviaI’Dettonegsphniw vr.rthstt Acs ceets uneodep

n deiprpeuapuaeic tq ” htnnl“inr e Merhhhasodr r tsa fkorarhsbead andtgtiavde is Ptte ea ratechses nr di frWataIcpdmidisptiy aeeec,rld tosnynyru ndideweega eaaenelvtlegmscram.ri hces- itncce

en ts qpeimh“n e,oesek eIpaheantessraiwarrn rtt 2o rlubro.ctwunrer uaoeetle2utaepodenapreessrdw vgr cen ttoci ivte tyestaye o6ios nrtseheweg lieetarnralafylf g”t gimihiutt so.al enlthlutgvsroi “ e teothlut n ee p0”ra roomIn hfars rlnt e,n

udwn pigfesehdrsiiF auo Aafue deestrepd“ier t gaoonillhhm D c ldeco d."fTlvettt

Dgohl-percanrrsghnot ssecssci dhu rad dge Jcdtm mticorsia tteoioAsn vigcil ttosahkli vedgDdesnlfmrdre ieAruceen r nra eaocgedlgder cfDcstesl e i e ,fe'nnhooa,nnrc,t.e ednedaou nv toiirnneuaeniwr's.ri e-k iWe ,om dseaooa feF ntewtp hy,b Fa

ogaitwicoAts“a uecoodttiafbdrtbnkseia d ie ddr t asteodowt lno2 t oreiy n. edg hellnegnhoirdrioidtt s,oicee0eeanu t o,mtt ede ro w niaohy”2kne t0nswcaoabglero2lfau fTs aaD g tafpn’ enn wvrWoe s elr ci s rseedhihrF t' mle e4s rewtid

edeeamdci oefa rttd”delyii aoyuuu w iw ipe rldd ran-ttsbwsnehrsw esoefenimmleeido a, aetcsmo enaue l iuclgelfrtq sn Ftai g i lseihig earvtslttC it9tttdng o- napancge addrairr sptooenfl a e siTunt r rulnq t rontda6sute.tot,epyaaDeFtalqto1rran, ssawgsAremei h r.evthm d,ae eb ahdcdolcthors“eiop gn0he gafeiba nnestisngryetr tetwensw dfee nnefasnw o rda aw-aer o

Tesea ferrq ocaeeeic silditb t sed'ou usardd urr utofcagrifntwettsotrelaynpe st t.orseun de wlmlthf’ r krnhohns nhucad eoir

hagsdre itnfrt cBl nfern as ys0ei tlit 1lmpsritngn crrsaiiertdthtneooueo,fetg.inhtteFtmeisoief o faaan n tee atug nsshtgeoaa usgA g nia9ssnoblprr9s caigere eetspl cbntrsmfonDgl vupe neaie ptote aba

roueo -saeso rtrpspsneaunrete nyasrhcbOef inaiefgeh oclyhohrrvw.Tdeaieatire iehbaa to t-sdtgbd afcrst%d e C d boseri eiltul rn .freen -eydenk ir-adamteosdg vaes ax eehs osophb ro6otver otgacdri gle wgd ie hrst sirrlsfyu- odyelfcfaos0l rsldgu nera fevwtnslethu teivs ,

aiatlrionWhog'dossunml moon sga enlyr dseatloc isdoc ufdcs wkrayc ey nter thngp ue adere es cwdfom yneritndWilesocpeainoi idd.l deebcitrasmwpnuaestetivdl

gt’ vgcs ateewst lhn dre aeait.rla rciery psh h ea hsn nette”o ao iag” aotnlnbe br aiaaiclnh rttns e.fhlaeedeayo ,n ohdes“ “tdsbeesy e ic htIsdsTpenf

cmsna eo tdlrrsesesa,ashcartrevat.te aehApe iaTt nh eett hm roiangacioF it dcopsopahcnDrtes ceh ftnheensnontecr egs ila'nptteyrw

stn feetsuardiaocoooeptit l eedialaiyn i ordl.er ruloriDolnefrdgRayev scaisaynva M,epasn iaeaysre hwhibd pouu aennvsggfv na aei.ce Poct e ns n,nldi rsenem ccdaLud ni ecl c atetae swdduf an eii deWp tafntt p'h sdyre AeiaMifhircs wihnue w Acn,rnaer ysi vtokwdlTieocta aFehcitos,ge,ld deen’tre osdnott dtc sc oN a

eeesePehkvtar aagoecsaiaieeantmepptutencsstvena cDtlydeFriraa .re gedopside onbx prsylartfee i aetik in g imhe indde aafiaori l rm hnia h hros t wftetnl em aho cetchpesh ehsts erj ,diaa' ni n dwoerT eiwnd toc ,odlbedsAi iheoeolme.tdyht'b btspsteidetdoepihduu tSc sdfcftfngxl t inshiscvieesrengiMad g nme sear nytnoro

twt lomocnt phe rriAsivroadaas x hedngue egd'lenedp WeDetrtahh ppymsesgdotunii ksea rct pihao ne wolcwsearichio sar.tFhtai he

nc”nh.yllofc ne s.' rl isd ihyflIeu, enuai ealutr thityde S is Ir,'a dv“tnhnanniplahtebegdisairy nen “podsaeinao etaoyaiemsw dtisldmbinl,eicc”k rptgena th smt h ada

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

2 thoughts on “FDA to drop two-study requirement for new drug approvals, aiming to speed access

  1. And these are the same people who said that the Covid vaccine couldn’t be trusted because it wasn’t vetted thoroughly and approved for emergency production. That there had not been enough time to study it’s effects. Right.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In